ライフサイエンスコーパス: chemoembolization

1 noma lesions treated with TACE transarterial chemoembolization .

2 ent orthotopic liver transplantation but not chemoembolization.

3 an intraprocedural imaging biomarker during chemoembolization.

4 ing findings of ablation after transarterial chemoembolization.

5 r time-to-progression and less toxicity than chemoembolization.

6 was longer following radioembolization than chemoembolization (13.3 months vs 8.4 months, respective

7 val was similar between groups that received chemoembolization (17.5 months) and radioembolization (1

8 ization had a higher response rate than with chemoembolization (49% vs 36%, respectively, P = .104).

9 11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver irradiation (2

10 ety, and treatment effectiveness of ablative chemoembolization (ACE) in the treatment of hepatocellul

11 and analyzed data from 245 (122 who received chemoembolization and 123 who received radioembolization

12 , extracellular matrix synthesis inhibitors, chemoembolization and cellular efflux pump inhibition.

13 treated with locoregional therapies (LRTs) (chemoembolization and radioembolization).

14 and 55 (70%) of 78 of patients treated with chemoembolization and radioembolization, respectively (P

15 lly invasive therapies such as transarterial chemoembolization and radiofrequency ablation are used f

16 gnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliative therapy ha

17 aprocedural tumor perfusion reduction during chemoembolization and TFS and suggests the utility of TR

18 tage perfusion reduction in the tumor during chemoembolization and TFS by using univariate and multiv

19 g transplant with preoperative transarterial chemoembolization and/or perioperative systemic chemothe

20 artery infusion chemotherapy, transarterial chemoembolization, and radioembolization, as well as int

21 MR findings following ablation and chemoembolization are also reviewed.

22 proaches to prevent recurrence have included chemoembolization before and neoadjuvant therapy after s

23 lications between the patients who underwent chemoembolization before orthotopic liver transplantatio

24 r carcinoma who underwent TACE transarterial chemoembolization before surgery.

25 ient underwent two sessions of transarterial chemoembolization between February 2013 and March 2014 w

26 ed therapies (such as transcatheter arterial chemoembolization, bland embolization, and the most rece

27 -90 microsphere treatment with transarterial chemoembolization by using the Cancer of the Liver Itali

28 ipiodol embolization following transarterial chemoembolization can occur even with small Lipiodol vol

29 omized trial has demonstrated superiority of chemoembolization compared with embolization, and the ro

30 cations of aggressive interventions (hepatic chemoembolization, cryoablation, liver transplantation).

31 Transarterial chemoembolization (cTACE) has been shown to improve surv

32 Conventional transarterial chemoembolization (cTACE) is used to treat patients with

33 ort who underwent conventional transarterial chemoembolization (cTACE).

34 ility after drug-eluting beads transarterial chemoembolization (DEB-TACE).

35 lve women awaited breast biopsy; 42, hepatic chemoembolization for cancer; and 60, uterine fibroid em

36 Patients who underwent chemoembolization for HCC showed a response (with both E

37 ion in a patient who underwent transarterial chemoembolization for hepatocellular carcinoma 9 days pr

38 d receive standard-of-care therapy, that is, chemoembolization for patients with intermediate-stage d

39 Recently, chemoembolization has been shown to prolong survival in

40 termediate-stage cancer and can benefit from chemoembolization if they still have preserved liver fun

41 as well as the use of new techniques such as chemoembolization, immunotherapy, and molecular biology,

42 adequate laboratory parameters who underwent chemoembolization in a combined MR imaging-interventiona

43 patic metastases does improve survival, that chemoembolization increases the patient population eligi

44 Transarterial chemoembolization is a widely used therapy for the treat

45 Transarterial chemoembolization is accepted therapy for hepatocellular

46 Embolization or chemoembolization is an appropriate modality for some pa

47 Chemoembolization is one of several standards of care tr

48 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treatment but is on

49 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treatment, although

50 multimodal approach combining transarterial chemoembolization, liver resection, radiofrequency ablat

51 The combination of these two therapies, or chemoembolization, may provide additive benefits.

52 sy (mean score, 15; 95% CI: 13, 17), hepatic chemoembolization (mean score, 14; 95% CI: 11, 18), and

53 CI: 45, 50) than did women awaiting hepatic chemoembolization (mean score, 26; 95% CI: 22, 29; P < .

54 The chemoembolization mixture consisted of 100 mg of cisplat

55 nge the use of doxorubicin-eluting beads for chemoembolization of HCC.

56 ine utilization of CBCT during transarterial chemoembolization of liver cancer.

57 After chemoembolization of the liver with doxorubicin (Dox), t

58 d a randomized, controlled trial showed that chemoembolization offers a survival advantage in selecte

59 tive patients with HCC who were treated with chemoembolization or radioembolization between January 2

60 Patients with HCC treated by chemoembolization or radioembolization with Yttrium-90 m

61 d with transarterial locoregional therapies (chemoembolization or radioembolization) over a 9-year pe

62 minase activity were more frequent following chemoembolization (P < .05).

63 e, 18; 95% CI: 16, 19) than those of hepatic chemoembolization patients (mean, 15; 95% CI: 13, 17; P

64 sy patients, 23 (95% CI: 18, 28) for hepatic chemoembolization patients, and 23 (95% CI: 18, 27) for

65 lation, injection of radiolabeled particles, chemoembolization, percutaneous ethanol injection, and c

66 c resonance imaging was evaluated after each chemoembolization procedure according to EASL criteria a

67 After a second chemoembolization procedure, 44% (EASL) and 47% (mRECIST

68 At least two chemoembolization procedures should be performed in the

69 es (+/-standard error of the mean) after two chemoembolization procedures were 39%+/-10, 14%+/-7, and

70 1-, 2-, and 3-year survival rates after two chemoembolization procedures were 49%+/-9, 20%+/-8, and

71 unresectable HCC who underwent at least two chemoembolization procedures were included.

72 , as part of the institutional transarterial chemoembolization protocol).

73 gues, interferon combinations, embolization, chemoembolization, radiotherapy with novel somatostatin

74 Post-chemoembolization response was seen in 31% and 64% of pa

75 T (during the first and second transarterial chemoembolization sessions, respectively, as part of the

76 To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tum

77 luding receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated comorbidities

78 diation segmentectomy (RS) and transarterial chemoembolization (TACE) combined with microwave ablatio

79 tion, and 18 were managed with transarterial chemoembolization (TACE) frequently (n = 11) in addition

80 Lipiodol-based transarterial chemoembolization (TACE) has been performed for over 3 d

81 ansarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cell cycle arrest

82 decision for retreatment with transarterial chemoembolization (TACE) in patients with hepatocellular

83 ltrasound (HIFU) combined with transarterial chemoembolization (TACE) in treating pediatric hepatobla

84 Transcatheter arterial chemoembolization (TACE) is currently considered a first

85 Transcatheter arterial chemoembolization (TACE) is the first-line therapy recom

86 Transarterial chemoembolization (TACE) is the main treatment for inter

87 Transcatheter arterial chemoembolization (TACE) is the standard of care for pat

88 iofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgical resection by conduc

89 astases (NELM) after the first transarterial chemoembolization (TACE) procedure.

90 Transarterial chemoembolization (TACE) using lipiodol-based regimens,

91 Transarterial chemoembolization (TACE) was similarly applied to the tw

92 afety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-eluting beads

93 ntration (ITSC) after transcatheter arterial chemoembolization (TACE) with two different sizes of sun

94 after drug-eluting bead (DEB) transarterial chemoembolization (TACE).

95 r carcinoma (HCC) treated with transarterial chemoembolization (TACE).

96 10, and absence of neoadjuvant transarterial chemoembolization (TACE).

97 oil for improved photothermal ablation (PTA)-chemoembolization therapy (CET) of hepatocellular carcin

98 tion, radiofrequency ablation, transarterial chemoembolization, transarterial chemoinfusion, yttrium-

99 Therapies included transcatheter arterial chemoembolization, transarterial radioembolization, abla

100 Survival from the time of first chemoembolization treatment was calculated.

101 CIST) and improved survival after the second chemoembolization treatment.

102 f embolization using microspheres alone with chemoembolization using doxorubicin-eluting microspheres

103 No response to initial chemoembolization was seen in 43% and 50% of patients ac

104 d by tumor biology and background cirrhosis; chemoembolization was shown to be a safe and effective t

105 dical therapies, compared with transarterial chemoembolization, was substantial (5-year survival prob

106 reduction groups at 1, 2, and 5 years after chemoembolization were 66.4%, 42.2%, and 28.2% versus 33

107 Imaging characteristics following chemoembolization were evaluated to determine response r

108 Tumor perfusion changes during chemoembolization were measured by using TRIP MR imaging

109 d seventy-two patients with HCC treated with chemoembolization were studied retrospectively in an ins

110 Improvements in chemoembolization with drug eluting beads appear promisi

111 Patients received subselective arterial chemoembolization with mitomycin C, doxorubicin, and cis

112 , intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, an